{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-327828","form_type":"8-K","ticker":"BMRN","cik":"0001048477","company_name":"BIOMARIN PHARMACEUTICAL INC","filed_at":"2025-12-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.654790+00:00","generated_at":"2026-05-16T12:23:04.215044+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"BioMarin ends development of oral AATD liver disease candidate BMN 349","bullets":["Discontinued BMN 349, an oral therapeutic for alpha-1 antitrypsin deficiency (AATD)-associated liver disease.","Decision announced on December 19, 2025; no reason for discontinuation disclosed.","No financial impact or pipeline replacement details provided in the filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-327828","json":"https://secwatch.observer/filing/0001193125-25-327828.json","markdown":"https://secwatch.observer/filing/0001193125-25-327828.md","text":"https://secwatch.observer/filing/0001193125-25-327828.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1048477/000119312525327828/0001193125-25-327828-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1048477/000119312525327828/d45090d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:23:04.215044+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}